Skip to main content

Table 1 Baseline characteristics between groups according final glucose status (n = 491)

From: Clinical and metabolomic predictors of regression to normoglycemia in a population at intermediate cardiometabolic risk

 

Overall (n = 491)

Regression to normoglycemia (n = 111)

IFG maintenance (n = 235)

Progressed to T2D (n = 145)

p value

Age (years)

48.72 ± 11.02

49.98 ± 11.2

48.35 ± 11.00

48.34 ± 10.87

0.27

Women n, (%)

327, (66.59)

75, (67.5)

161, (68.5)

91 (62.7)

0.498

Hypertension

341 (69.45)

76, (68.4)

173, (73.6)

92, (63.4)

0.262

Years of education

11.72 ± 5.01

12.52 ± 5.41

11.61 ± 4.99

11.29 ± 4.68

0.061

BMI (kg/m2)

30.15 [6.3]

29.45[6.4]

30.00 [5.5]

30.78 [7.25]

0.049*

Obesity n, (%)

248 (50.5)

51 (45.9)

116 (49.36)

81 (55.86)

0.258

Abdominal obesity n, (%)

298 (60.6)

58 (52.2)

144 (61.27)

96 (66.2)

0.074

Sedentary habit n, (%)

348 (70.8)

76, (68.4)

169, (72)

103, (71)

0.804

Fasting glucose (mg/dL)

105.00 [8]

103.00 [6]

105.00 [8]

108.00 [12]

0.001*

Fasting insulin (UI)

14.80 [11.2]

13.80 [11.05]

15.05 [10.2]

14.6 [11.5]

0.508

HOMA-IR

3.92 [2.9]

3.6 [2.9]

4.0 [2.7]

3.95 [3.28]

0.285

HOMA-B

46.83 [37.23]

44.50 [39.91]

47.41 [34.6]

46.02 [38.67]

0.673

METS-IR

49.40 [12.11]

48.45 [13]

49.44 [11.3]

50.48 [12.2]

0.289

Triglycerides (mg/dL)

197.00 [121]

200.00 [169]

188.00 [112]

205.00 [116]

0.542

Hypertriglyceridemia n, (%)

355 (72.3)

76 (68.4)

169 (71.9)

110 (75.86)

0.417

Total-cholesterol (mg/dL)

217.42 ± 42.70

224.69 ± 45.3

214.39 ± 43

216.76 + 39.44

0.184

HDL-c (mg/dL)

42.14 ± 10.65

43.05 ± 10.11

41.29 ± 10.10

42.82 ± 11.84

0.987

LDL-c (mg/dL)

134.51 ± 32.74

138.78 ± 31.0

133.77 ± 35.04

132.60 + 29.83

0.232

Apolipoprotein-B (mg/dL)

116.00 [38.4]

120.0 [36.5]

115.00 [39.35]

115.00 [37]

0.712

  1. Abdominal obesity male > 102 cm, female > 88 cm. Hypertension: > 130 mmHg or > 88 mmHg or taking antihypertensive medication, or self-report of previous diagnosis
  2. ATP III adult treatment panel III, IFG impaired fasting glucose IFG, T2D type 2 diabetes, BMI body mass index (kilogram/height2), HDL-C high-density lipoprotein cholesterol, LDL-c low-density lipoprotein-cholesterol, HOMA-IR Homeostasis Model Assessment for Insulin Resistance (fasting glucose * fasting insulin/405), hypertriglyceridemia: fasting triglycerides > 150 mg/dL
  3. One-way ANOVA was used to compute the p value between three groups